Loading...

BFRI BIOFRONTERA INC US FDA Inspections 8-K Filing

BFRN

BFR

BIOFRONTERA INC

(BFRI)

2024 8-K

Financial Results Report

Study Results Announcement

Patent Dispute Update

Study Results Unveiled

Preliminary Revenue Update

Nasdaq Compliance Notice

Financial Results Announced

Compliance Regained

Asset Sale Announced

Strategic Transaction

Asset Purchase Agreement

Stockholder Approvals

Financial Results Update

Asset Acquisitions

Asset Acquisitions

Management Changes

Proxy Statement Supplement

Notice of Delisting

Financial Statements

Failure to Satisfy Listing ...

Accountant Change

Financial Results

Capital Structure Change

Financial Results

Financial Results

Increase in Authorized Shares

Compliance Notice

Financial Results Announcement

Achievement of Milestones a...

Amendment to Incorporation ...

Meeting of Stockholders

Record Date Change

Stockholder Director Nomina...

Results of Operations and F...

Securities Purchase Agreement

LSA Amendment and Securitie...

Recall of Ameluz

FDA Review of Ameluz Dosage...

Amendment and Exercise of W...

Earnings Report

Termination of Loan Agreement

Settlement Agreement with M...

Loan Agreements

Annual Meeting of Stockholders

Agreement Addendum

Earnings Report

Public Offering

Amendment to Settlement Agr...

FDA Approval and Patent Filing

Financial Results

Reaudited Consolidated Fina...

Earnings Reports

Accountant Change

Resignation of Accountant

Product Development

Management Appointment

Resignation and Appointment

Results of Operations and F...

Amendment to Stockholder Ri...

Settlement Agreement

Earnings Report

Delisting Notice

Financial Results

External Links:

Biofrontera Inc. announced that the FDA has completed its filing review and will conduct a substantive review of the company's application to increase the approved dosage of Ameluz.

AI Assistant

BIOFRONTERA INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.